Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 401–500 of 688
Liu, J., Xie, Y., Lu, Y., Zhao, Z., Zhuang, Z., Yang, L., Huang, H., Li, H., Mao, Z., Pi, S., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221205 · Cited by 17
“Tight junctions in cerebral endothelial cells include the Occludin protein family and the Zonula occludins protein family [35, 36].”
Self-citationLiu, P., Thomson, B. R., Khalatyan, N., Feng, L., Liu, X., Savas, J. N., Quaggin, S. E., & Jin, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807982115 · Cited by 17
“The selectivity of these barriers to serum proteins can be altered by the disruption of barrier structure in pathological conditions; for example, breakdown of the BBB leads to leakages and perivascular accumulation of blood-derived fibrinogen, thrombin, albumin, IgG, and hemosiderin deposits (33).”
BackgroundJin, L., Pan, Y., Tran, N. L. L., Polychronopoulos, L. N., Warrier, A., Brouwer, K. L. R., & Nicolazzo, J. A. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01227 · Cited by 17
Not just neurons: The diverse cellular landscape of learning and memory
Alberini, C. M. (2025) · Neuron · doi:10.1016/j.neuron.2025.05.005 · Cited by 17
Immunometabolism Reframes Alzheimer’s Disease: From Systemic Dysmetabolism to Glial Rewiring
Bach, D., & Nguyen, L. L. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01691-0 · Cited by 17
“Mechanistically, endothelial GLUT1 downregulation cur-tails glucose entry; and while BBB lactate transport can be altered in models, consistent human evidence for reduced BBB MCT1 is lacking (Winkler et al. 2015; Montagne et al. 2017; Knox et al. 2022 ).”
Frank, C. J., & McNay, E. C. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13074 · Cited by 17
Junceda, S., Cruz‐Alonso, M., Fernández, B., Pereiro, R., Martínez‐Pinilla, E., & Navarro, A. (2024) · Biomolecules · doi:10.3390/biom14030295 · Cited by 18
“On the other hand, this vascular process may be responsible for the progressive reduction in cerebral blood flow, triggering oxidative stress and the subsequent death of astrocytes and neurons, particularly in energy-demanding brain regions like the cortex and hippocampus [43,44].”
BackgroundBeishon, L., Panerai, R. B., Robinson, T. G., Subramaniam, H., & Haunton, V. J. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180068 · Cited by 16
“Furthermore, amyloid accumulation results in blood-brain barrier dysfunction, protein leakage, and further neuronal toxicity [5, 32, 33].”
BackgroundMuramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
Piec, P.-A., Pons, V., Préfontaine, P., & Rivest, S. (2022) · Cells · doi:10.3390/cells11142241 · Cited by 17
Sex and gender differences in dementia
Salwierz, P., Davenport, C., Sumra, V., Iulita, M. F., Ferretti, M. T., & Tartaglia, M. C. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.002 · Cited by 17
Contribution of Direct Cerebral Vascular Transport in Brain Substance Clearance
Wen, Q., Wang, H., Haacke, E. M., Jiang, Q., & Hu, J. (2024) · Aging and Disease · doi:10.14336/ad.2023.0426 · Cited by 20
“For example, damages to cerebro-vasculature, such as the increased vascular permeability or transporter dysfunction across BBB, were associated with AD pathologies (Aβ and tau) and contributed to the onset and progression of AD [67, 177-183].”
BackgroundWu, W., Huang, J., Han, P., Zhang, J., Wang, Y., Jin, F., & Zhou, Y. (2023) · Molecules · doi:10.3390/molecules28227631 · Cited by 15
“These changes are accompanied by cytoplasmic vacuolization, atrophy, and swelling of astrocyte end pods [108,109].”
BackgroundSomatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Sandoval, K. E., & WITT, K. A. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001117 · Cited by 19
“BBB breakdown attributed to A b and inflammation occurs in both human AD and preclinical AD models (Montagne et al., 2017).”
Alzheimer-Associated Neuronal Thread Protein: Research Course and Prospects for the Future
He, J., & Wang, R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201273 · Cited by 17
“Based on evidential extrapolations, AD7c-NTP is the product of brain degeneration, which the CSF discards to maintain homeostasis [23, 32].”
Subcommissural Organ-Spondin-Derived Peptide Restores Memory in a Mouse Model of Alzheimer’s Disease
Douce, J. L., Delétage, N., Bourdès, V., Lemarchant, S., & Godfrin, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.651094 · Cited by 15
Joseph, C. R. (2021) · Diagnostics · doi:10.3390/diagnostics11101888 · Cited by 15
“Because of the deadly n ture of hpTau and its prop nsity to spre d tr nssynaptic lly as well as by exost sis in a Prion-like fashion, its appearance is the irretrievable end of the road [24].”
BackgroundNucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities
Soelter, T. M., Whitlock, J. H., Williams, A. S., Hardigan, A. A., & Lasseigne, B. N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09239 · Cited by 16
“Over 20 research studies have implicated the breakdown of the BBB in samples for AD patients, before the onset of symptoms associated with AD or mild cognitive impairment (MCI), a pre-dementia form of the disease [21].”
BackgroundThe Lipid Invasion Model: Growing Evidence for This New Explanation of Alzheimer’s Disease
Rudge, J. D. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221175 · Cited by 15
Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood–Brain Barrier
D'Arrigo, J. S. (2018) · Biomimetics · doi:10.3390/biomimetics3010004 · Cited by 17
“An early BBB breakdown and/or dysfunction has been documented in Alzheimer’s disease before dementia, neurodegeneration, and/or brain atrophy occur, and investigators have reported that targeting the BBB can influence the course of such neurological disorder [92].”
León-Arcia, K., Andrade-Guerrero, J., Martínez-Orozco, H., Villegas-Rojas, M. M., Pérez-Segura, I., Ramírez, I. L., Vilches‐Flores, A., Guerra‐Crespo, M., Díaz-Miranda, S. Y., & Soto-Rojas, L. O. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102918 · Cited by 14
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
“Further, under pathological conditions, the BBB becomes more permeable, increasing CNS vulnerability to Disease and pathogens [90, 92, 93].”
Cell-free RNA signatures predict Alzheimer’s disease
Cisterna‐García, A., Beric, A., Ali, M., Pardo, J. A., Chen, H., Fernández, M. V., Norton, J. B., Gentsch, J., Bergmann, K., Budde, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108534 · Cited by 14
“51,52 We have also built predictive models that correctly classify presymptomatic AD and control participants with a reasonable number of transcripts, and that showed high accuracy and specificity for AD.”
BackgroundEnvironmental mycotoxins: A potential etiological factor for neurodegenerative diseases?
Nie, T., Li, J., You, L., & Wu, Q. (2025) · Toxicology · doi:10.1016/j.tox.2025.154056 · Cited by 15
Guo, P. F., Zhang, W., Lian, T., Zhang, W.-J., He, M., Zhang, Y.-N., Huang, Y. M., Ding, D.-Y., Guan, H., Li, J., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360250 · Cited by 16
“These actions together acted to destroy the ability of the BBB to function (Montagne et al., 2017).”
An automated method for segmentation and quantification of blood vessels in histology images.
Bukenya, F., Nerissa, C., Serres, S., Pardon, M.-C., & Bai, L. (2020) · Microvascular Research · doi:10.1016/j.mvr.2019.103928 · Cited by 10
Silva, J. R., Patricio, F., Patricio-Martínez, A., Santos‐López, G., Cedillo, L., Tizabi, Y., & Limón, I. D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.867825 · Cited by 14
Aducanumab delivery via focused ultrasound-induced transient blood–brain barrier opening in vivo
Jeong, J., Han, M., Jeon, S., Kim, Y., Choi, H. J., Choi, W., Kwon, K., Choi, J.-R., & Lee, E.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-02412-1 · Cited by 13
“Although AD mouse models exhibit a compromised BBB, the extent and heterogeneity of BBB disruption vary significantly depending on disease progression and model characteristics 37,38 .”
Mohan, K., Gasparoni, G., Salhab, A., Orlich, M. M., Geffers, R., Hoffmann, S., Adams, R. H., Walter, J., & Nordheim, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031044 · Cited by 13
Hossen, F., Geng, X. H., Sun, G. Y., Yao, X., & Lee, J. C. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04138-z · Cited by 13
“Alteration of the blood brain barrier (BBB) function is an early manifestation in AD [109–112].”
Dai, C., Xu, Y., Ke, L., Zhu, M., Deng, R., Wang, X., & Zhou, Y. (2025) · ACS Sensors · doi:10.1021/acssensors.4c02916 · Cited by 13
Torres, V. O., Pizzo, M. E., Chan, D., Dugas, J. C., Huynh, D., Joy, D. A., Liang, E., Sarrafha, L., Becerra, I. A., Chau, R., et al. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251361997 · Cited by 17
“19,26 All of these factors have the potential to impact the effectiveness of RMT-based delivery of CNS drugs.”
Bioluminescence Imaging with Functional Amyloid Reservoirs in Alzheimer’s Disease Models
Yang, J., Ding, W., Zhu, B., Zhen, S. Y., Kuang, S., Yang, J., Zhang, C. M., Wang, P., Yang, F., Yang, L., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02358 · Cited by 13
Contu, L., Carare, R. O., & Hawkes, C. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12556 · Cited by 13
Shedding Light on the Blood–Brain Barrier Transport with Two-Photon Microscopy In Vivo
Kucharz, K., Kutuzov, N. P., Zhukov, O., Janiurek, M. M., & Lauritzen, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03266-2 · Cited by 16
“Notably, AMT increase appears to be the earliest sign of BBB dysfunction, preceding loss of junctional complexes and opening of the BBB (85), and may facilitate the onset and progression of neurodegeneration in chronic brain disorders (80, 89).”
BackgroundPericytes modulate endothelial inflammatory response during bacterial infection
de Carvalho, T. P., Toledo, F., Bautista, D. F. A., Silva, M. F., Oliveira, J. B. S., de Lima, P. A., Costa, F. B., Ribeiro, N. Q., Lee, J., Birbrair, A., et al. (2024) · mBio · doi:10.1128/mbio.03252-23 · Cited by 12
“For instance, decreased pericyte coverage over blood vessels of the subcortical white matter of Alzheimer’s disease patients was related to changes in vascular density and high accumulation of blood-derived extravascular fibrin deposits (67).”
BackgroundTamberi, L., Belloni, A., Pugnaloni, A., Rippo, M. R., Olivieri, F., Procopio, A. D., & Bronte, G. (2024) · Cells · doi:10.3390/cells13070643 · Cited by 13
“[22], leads to the infiltration of immune cells in the brain parenchyma.”
BackgroundFang, X., Border, J. J., Zhang, H., Challagundla, L., Kaur, J., Hwang, S. H., Hammock, B. D., Fan, F., & Roman, R. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062433 · Cited by 12
Hou, J., Jiang, D., Chu, M. K., & Wu, L. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03347-x · Cited by 15
“Therefore, reducing the disruption of the BBB could serve as a potentially useful therapeutic approach to limit the harmful in fi ltration of peripheral immune cells into the central nervous system.”
Molecular Aspects of Geriatric Pharmacotherapy
Rzeczycki, P., Pęciak, O., Plust, M., & Droździk, M. (2025) · Cells · doi:10.3390/cells14171363 · Cited by 12
Dai, M., Lin, Y., El‐Amouri, S. S., Kohls, M., & Pan, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197379 · Cited by 13
Stevenson, T. K., Moore, S. J., Murphy, G. G., & Lawrence, D. A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1740265 · Cited by 12
Research advances in the influence of lipid metabolism on cognitive impairment
Zhang, M., Zhu, Y., & Zhu, Z. (2022) · Ibrain · doi:10.1002/ibra.12018 · Cited by 14
“59 According to another study, 60 a high ‐ fat diet can lead to excessive production of circulating free fatty acids, systemic inflammation, and local inflammation.”
BackgroundKline-Schoder, A. R., Noel, R. L., Phatnani, H. P., Menon, V., & Konofagou, E. E. (2023) · Neuroglia · doi:10.3390/neuroglia4020010 · Cited by 13
“This correlation is weaker but present in the naive AD brain, likely due to the AD-related increase in blood–brain barrier permeability [51].”
BackgroundRaut, S., Patel, R., Pervaiz, I., & Al-Ahmad, A. J. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.01.007 · Cited by 13
Wang, C., Kong, J., Xue, C., Zhang, T., & Wang, Y. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200825 · Cited by 12
Siu, A. C. W., Paudel, K. R., Singh, G., Gupta, G. K., Singh, S. K., Chellappan, D. K., Rubis, G. D., Pathak, S., Oliver, B. G. G., Dua, K., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05428-3 · Cited by 13
“Notably, early BBB breakdown and dysfunction play a critical role in the development and progression of AD [132].”
Hirao, K., Yamashita, F., Tsugawa, A., Haime, R., Fukasawa, R., Sato, T., Okita, M., Shimizu, S., Kanetaka, H., Umahara, T., et al. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13767 · Cited by 11
Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders
Bicker, J., Alves, G., Fonseca, C., Falcão, A. C., & Fortuna, A. C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105226 · Cited by 11
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Sahib, S., Tian, Z. R., Bryukhovetskiy, I., Manzhulo, I., Menon, P. K., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.04.008 · Cited by 12
Gut Microbes Regulate Innate Immunity and Epilepsy
Zhang, L., Li, S., Tai, Z., Yu, C., & Xu, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.870197 · Cited by 13
“Blood–Brain Barrier The BBB acts as the dividing line between the central and peripheral parts, preventing blood cells, pathogens, and poisons from entering the brain (Montagne et al., 2017).”
BackgroundChen, R., Morris, B. J., Donlon, T. A., Ross, G. W., Kallianpur, K. J., Allsopp, R., Nakagawa, K., Willcox, B. J., & Masaki, K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230350 · Cited by 12
“:3) in perivascular spaces leading to disruption of the blood-brain barrier [2, 3].”
Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options
Cooper, C. G., Kafetzis, K. N., Patabendige, A., & Tagalakis, A. D. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16229 · Cited by 11
“BBB disruption is proposed to contribute to both the onset and progression of AD (Montagne et al., 2017), as neuroimaging has shown that BBB disruption is observed in the hippocampus of AD-affected brains predating brain atrophy and dementia (Montagne et al., 2015).”
BackgroundJiang, L., Wang, Q., Jiang, Y., Peng, D., Zong, K., Li, S., Xie, W., Zhang, C., Li, K., Wu, Z., et al. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117892 · Cited by 11
A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimer’s Disease
Arora, S., Sharma, D., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00611 · Cited by 12
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 11
Tatarciuc, D., Curca, F. R., Virvescu, D. I., Butnaru, O., Goriuc, A., Bida, S. M., Luchian, I. A., Surlari, Z., Scurtu, M., Ursu, R. G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196696 · Cited by 10
“However, as AD progresses, salivary function and oral hygiene can diminish, worsening oral disease and creating a vicious cycle [63].”
Siddiqui, T., Çelikkaya, H., Atasavum, Z. T., Popova, S. D., Freudenberg, U., Werner, C., & Kızıl, Ç. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2655-9_8 · Cited by 11
Takechi, R., Sharif, A., Brook, E., Majimbi, M., Chan, D. C., Lam, V., Watts, G. F., & Mamo, J. C. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127481 · Cited by 10
“The breakdown of cerebral capillary BBB is reported in late onset AD and indeed ordinarily precedes by decades the pathophysiological hallmarks of amyloidosis, tau hyperphosphorylation, cognitive decline and brain atrophy, consistent with causality (12).”
BackgroundJiang, G., Long, Z., Wang, Y., Wang, Y., Xue, P., Chen, M., Yang, K., & Li, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14133 · Cited by 10
Hao, Z., Liu, K., Zhou, L., & Chen, P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1193031 · Cited by 11
“In normal brain, Aβ protein is transported from the brain to the brain via the BBB, whereas abnormal BBB function may lead to impairment of this process and abnormal clearance of Aβ transport thus causing Aβ deposition (Nelson et al., 2016; Montagne et al., 2017; Profaci et al., 2020).”
BackgroundDelivery of RNA to the Blood-Brain Barrier Endothelium Using Cationic Bicelles
Cheng, J., Wang, L., Guttha, V., Haugstad, G. D., & Kandimalla, K. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082086 · Cited by 10
“The cerebrovascular pathology is primarily characterized by the loss of blood-brain barrier (BBB) integrity and function, which can be observed in both Alzheimer’s patients [2] and transgenic mice models of AD [3].”
BackgroundChaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.009 · Cited by 11
“In addition, emerging evidence indicates that patients with AD have a dysfunctional blood-brain barrier (BBB) [5,6].”
BackgroundMouse serum albumin induces neuronal apoptosis and tauopathies
Hou, S., Huang, Y., Zhu, J., Jia, Y., Niu, X.-Y., Yang, J.-J., Yu, X., Du, X.-Y., Liang, S., Cui, F., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01771-6 · Cited by 11
“Elderly people often present with impaired BBB, and more attention has been paid to the correlation between disrupted BBB and neurodegenerative diseases [27, 28].”
BackgroundSaji, N., Toné, S., Murotani, K., Yagita, Y., Kimura, K., & Sakurai, T. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.01.020 · Cited by 10
Ahn, H. J., Baker, S. K., Norris, E. H., & Strickland, S. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.007 · Cited by 10
Lukiw, W. J. (2020) · Integrative Food Nutrition and Metabolism · doi:10.15761/ifnm.1000277 · Cited by 10
“Indeed, while Bacteroides fragilis is an anaerobic bacillus and part of the normal microbiota of the human colon and is generally commensal, this microbe can cause a ‘smoldering’ systemic infection if displaced into the bloodstream or surrounding tissue following disease, trauma or surgery [58,60-66].”
BackgroundKubicová, L., Bachmann, G., Weckwerth, W., & Chobot, V. (2022) · Cells · doi:10.3390/cells11060958 · Cited by 10
“Nevertheless, the polyphenols’ entrance into the brain tissues can be increased by pathological damage to the blood–brain barrier, which is associated with neurodegenerative disease [84].”
BackgroundHirao, K., Yamashita, F., Sakurai, S., Tsugawa, A., Haime, R., Fukasawa, R., Sato, T., Kanetaka, H., Umahara, T., Sakurai, H., et al. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14211 · Cited by 10
Supplemental thiamine as a practical, potential way to prevent Alzheimer's disease from commencing
Fessel, J. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12199 · Cited by 12
Shao, X., Shou, Q., Felix, K., Ojogho, B., Jiang, X., Gold, B. T., Herting, M. M., Goldwaser, E. L., Kochunov, P., Hong, L. E., et al. (2024) · eLife · doi:10.7554/elife.96155.2 · Cited by 12
Glaesser, D., & Iwig, M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109888 · Cited by 9
Using Neuroimaging to Study Cerebral Amyloid Angiopathy and Its Relationship to Alzheimer’s Disease
Wheeler, K. V., Irimia, A., & Braskie, M. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230553 · Cited by 10
“Disruption of the BBB through amyloid-related weakening of the cerebral vessel walls is a significant consequence of CAA [128] and may be an initial pathological event in AD [129].”
Magrì, A. L., Tomasello, B., Николаевна, Н. И., Tabbì, G., Cairns, W. R. L., Greco, V., Sciuto, S., Mendola, D. L., & Rizzarelli, E. (2024) · Biomolecules · doi:10.3390/biom14091104 · Cited by 10
Apolipoprotein E Drives Early Blood–Brain Barrier Damage in Alzheimer’s Disease
Zhang, Q., & Xie, C. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00596-2 · Cited by 9
Yu, G.-X., Initiative, A. D. N., Zhang, T., Hou, X., Ou, Y., Hu, H., Wang, Z.-T., Guo, Y., Xu, W., Tan, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201117 · Cited by 10
“In addition, impaired FDG-PET uptake could also reflect dysfunction in blood-brain barrier (BBB) transport systems [40, 41].”
BackgroundMa, C., Yang, L., Gao, Q., & Wang, L. (2022) · Disease Markers · doi:10.1155/2022/6967573 · Cited by 9
“BBB is the barrier between plasma and brain that protects mammalian brain from viruses, microorganisms, chemical molecules, and other harmful proteins in blood [2].”
BackgroundInfluentialProgresses in the establishment, evaluation, and application of in vitro blood–brain barrier models
Yin, P., & Wang, X. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25359 · Cited by 8
“AD patients lose significant numbers of pericytes in the cortex and hippocampus, suggesting that pericyte dysfunction contributes to BBB disintegration in AD (Montagne et al., 2017; Sweeney et al., 2018).”
BackgroundYao, M., Sun, N., Linville, R. M., Wei, Z., Kakazu, A., Ouyang, Y., Li, R., Du, L., Wang, H., Zhou, Y., et al. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00756-4 · Cited by 8
Three-Dimensional Imaging of Fibrinogen and Neurovascular Alterations in Alzheimer’s Disease
Merlini, M., Sözmen, E. G., Subramanian, K. S., Nana, A. L., Seeley, W. W., & Akassoglou, K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2655-9_5 · Cited by 8
Barman, R., Saikia, J., Sarmah, P., Konwar, P., Kumar, M., Bora, P. K., Bhattacharyya, P., Saikia, S. P., Haldar, S., & Banik, D. (2023) · South African Journal of Botany · doi:10.1016/j.sajb.2023.06.030 · Cited by 8
Expanding the brain researcher's toolkit
Gradinaru, V. (2020) · Science · doi:10.1126/science.abd2660 · Cited by 8
Blood-Brain Barrier Function as a Biomarker in Toxicology: Impact of Environmental Toxicants
Kelly, G., Watase, C. K., & Ho, D. H. (2023) · Biomarkers in disease · doi:10.1007/978-3-031-07392-2_36 · Cited by 8
McLarnon, J. G. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191106095038 · Cited by 9
Depression as a risk factor for Alzheimer’s disease: A human post-mortem study
Morisaki, M., Rezaali, F., Lau, L. C., Boche, D., Khandaker, G. M., Turecki, G., & Sinclair, L. I. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320561 · Cited by 7
“However, it is important to note that blood-brain barrier (BBB) failure, which is seen at the early stage of AD [78], can be caused by increased ICAM-1 expression [79].”
Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease
Korkmaz, F., Gimenez–Roig, J., Sultana, F., Laurencin, V., Sen, F., Cullen, L., Sims, S. L., Pallapati, A., Rojekar, S. V., Burganova, G., et al. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.05.001 · Cited by 8
Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease
Li, X., Li, Z., Chen, H., Guo, H., Ge, Y., Dong, F., Zhang, F., & Zhang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115199 · Cited by 8
Yang, Y., Chen, H., Liu, Q., Niu, Y., Mao, C., & Wang, R. Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1623050 · Cited by 8
“Cerebrovascular endothelial cells enable the selective passage of nutrients and molecules essential for brain function while preventing the ingress of neurotoxic substances (Alkhalifa et al., 2023; Montagne et al., 2017).”
Wu, E., Li, X., Ni, Z., Zhao, F., & Jia, C. (2026) · Journal of Oral Microbiology · doi:10.1080/20002297.2026.2616138 · Cited by 9
“Furthermore, the oral microbiome participates in AD pathological progression by mediating systemic inflammatory responses [86].”
Cerebral Infarction: Epidemiology, Classification, Mechanisms, Diagnosis, and Management
Zhang, M., Hou, J., Kuang, J. C., Hao, L., & Yang, Z. (2026) · MedComm · doi:10.1002/mco2.70704 · Cited by 10
A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta
Zhang, H., Xu, Q. F., Zhao, Y., He, N., Ren, Z., Xiang, Q., Tang, Z., & Liu, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673269288231123095215 · Cited by 8
Li, G., Ma, Y., Zhang, S., Lin, W., Yao, X. Y., Zhou, Y., Zhao, Y., Rao, Q., Qu, Y.-J., Gao, Y., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103415 · Cited by 8
“BMECs were recognized as playing crucial roles not only in ischemic stroke pathophysiology but also in many other deleterious CNS diseases such as Alzheimer ’ s disease [135], Parkinson ’ s disease [136], and multiple sclerosis [137].”
Philippi, S. M., Kailash, B. P., Raj, T., & Castellano, J. M. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52250 · Cited by 7
Wen, T., Meng, L., Liu, H., Zhang, Q., Dai, L., Huang, L., Liang, D., Zhu, K., Luo, J., & Zhang, Z. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01366-8 · Cited by 8
“These clinical findings align with animal studies suggesting that fibrin deposition exacerbates neurodegeneration [17].”
Tognatta, R., Merlini, M., Yan, Z., Schuck, R., Davalos, D., & Akassoglou, K. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100638 · Cited by 8
“Fibrinogen induces microglial activation (Adams et al., 2007; Davalos et al., 2012) and has been causally linked to neurodegeneration, neuroinflammation and autoimmunity in animal models of Alzheimer’s disease (AD), multiple sclerosis, and brain trauma (Merlini et al., 2019; Petersen et al., 2018).”
BackgroundMethodBhattacharjee, S., & Bhattacharyya, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00519 · Cited by 7
Skuja, S., Jain, N., Smirnovs, M., & Murovska, M. (2022) · Biomedicines · doi:10.3390/biomedicines10040830 · Cited by 7
Taghadosi, Z., Zarifkar, A., Razban, V., & Aligholi, H. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01044-y · Cited by 8
“There is a correlation between neurological disorders, cerebrovascular dysfunction, and BBB function changes (Montagne et al. 2017).”
BackgroundPericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders
Kim, H., Wu, K. L., Tam, K.-W., Chan, Y., & Shum, D. K. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.12.007 · Cited by 7
“Signs of BCB dysfunction in the brain can be detected early on in AD patients, preceding cognitive decline (Montagne et al., 2017).”
BackgroundEmerging concepts towards a translational framework in Alzheimer’s disease
Cozachenco, D., Zimmer, E. R., & Lourenco, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105246 · Cited by 8
Vesković, A., Nakarada, Đ. J., Pavićević, A. A., Prokić, B., Perović, M., Kanazir, S., Popović-Bijelić, A. D., & Mojović, M. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210324121156 · Cited by 7
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.